Ocugen (NASDAQ:OCGN) Upgraded by Wall Street Zen to “Hold” Rating

Ocugen (NASDAQ:OCGN) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other equities analysts have also issued reports on OCGN. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Ocugen in a research note on Thursday, March 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Oppenheimer started coverage on Ocugen in a report on Wednesday, March 11th. They set an “outperform” rating and a $10.00 price objective for the company. Finally, Canaccord Genuity Group initiated coverage on shares of Ocugen in a research report on Tuesday. They set a “buy” rating and a $12.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $9.00.

Ocugen Price Performance

Shares of OCGN stock opened at $2.04 on Friday. Ocugen has a 1 year low of $0.56 and a 1 year high of $2.72. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 8.04. The firm’s 50 day moving average is $1.73 and its 200-day moving average is $1.51. The firm has a market capitalization of $668.91 million, a price-to-earnings ratio of -8.87 and a beta of 2.75.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The firm had revenue of ($0.19) million during the quarter, compared to analysts’ expectations of $0.86 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. Sell-side analysts forecast that Ocugen will post -0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Ocugen

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Ocugen by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 15,223,585 shares of the company’s stock valued at $24,814,000 after acquiring an additional 450,904 shares during the last quarter. Millennium Management LLC grew its holdings in Ocugen by 29.7% during the fourth quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock valued at $7,285,000 after purchasing an additional 1,234,268 shares during the period. UBS Group AG grew its holdings in Ocugen by 373.2% during the fourth quarter. UBS Group AG now owns 4,849,353 shares of the company’s stock valued at $6,547,000 after purchasing an additional 3,824,474 shares during the period. State Street Corp increased its stake in Ocugen by 193.6% in the fourth quarter. State Street Corp now owns 3,978,738 shares of the company’s stock valued at $5,371,000 after purchasing an additional 2,623,361 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Ocugen by 3.9% in the fourth quarter. Geode Capital Management LLC now owns 3,819,242 shares of the company’s stock valued at $5,159,000 after purchasing an additional 142,050 shares in the last quarter. 10.27% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Oppenheimer initiated coverage with an Outperform (Buy) rating and a $10 price target, calling Ocugen an emerging leader in gene therapy for blinding ocular disorders — a major analyst endorsement that can attract institutional interest. Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating
• Positive Sentiment: Canaccord Genuity initiated coverage with a Buy rating and $12 price target, highlighting three clinical-stage retinal programs and “interesting” early data — another bullish analyst view that supports higher upside expectations. Canaccord Initiates Coverage of Ocugen, Inc. (OCGN) with a Buy Rating and a $12 Price Target
• Positive Sentiment: Ocugen announced it gained $15 million in a prior registered direct offering, extending its cash runway into 2027 — reduces immediate financing pressure and lowers short-term insolvency risk. Ocugen Gains $15 Million, Extends Cash Runway to 2027
• Neutral Sentiment: Analyst and trade commentary outlined a pipeline calendar of 2026–2027 catalysts (pivotal data, filings across three programs) that could drive large swings — important for timing but binary in outcome. OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
• Neutral Sentiment: Multiple outlets summarized the new coverage notes (Canaccord/Oppenheimer), increasing visibility but duplicating the same catalyst-driven narrative. Ocugen (OCGN) Receives a New Rating from Canaccord Genuity
• Negative Sentiment: Zacks flagged rising cash burn and dilution risk as Ocugen advances late‑stage programs — investors should expect financing needs and potential share issuance if data or revenue don’t materialize. Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
• Negative Sentiment: Short-term market reaction showed a share decline and underperformance in recent session(s), reflecting the tug-of-war between bullish analyst targets and financing/data risks. Ocugen Inc. stock falls Wednesday, underperforms market

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.